These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical pharmacokinetics of anti-parkinsonian drugs. Cedarbaum JM Clin Pharmacokinet; 1987 Sep; 13(3):141-78. PubMed ID: 3311529 [TBL] [Abstract][Full Text] [Related]
3. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634 [TBL] [Abstract][Full Text] [Related]
4. Decrease in liver aromatic L-amino-acid decarboxylase produced by chronic administration of L-dopa. Dairman W; Christenson JG; Udenfriend S Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2117-20. PubMed ID: 5289371 [TBL] [Abstract][Full Text] [Related]
5. Coenzyme--substrate adducts as inhibitors of mouse liver 3,4-dihydroxyphenylalanine decarboxylase. Rudd EA; Cunningham WC; Thanassi JW J Med Chem; 1979 Mar; 22(3):233-7. PubMed ID: 423204 [TBL] [Abstract][Full Text] [Related]
6. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity. Tran N Experientia; 1972 Sep; 28(9):1021-2. PubMed ID: 4665286 [No Abstract] [Full Text] [Related]
8. L-DOPA-chlorpromazine antagonism on running activity in mice. Derkach P; Larochelle L; Bieger D; Hornykiewicz O Can J Physiol Pharmacol; 1974 Feb; 52(1):114-8. PubMed ID: 4825682 [No Abstract] [Full Text] [Related]
9. Enhancement of the pharmacological action of 3,4-dihydroxy-L-phenylalanine(L-dopa) and reduction of dopa decarboxylase activity in rat liver after chronic treatment with L-dopa. Tanaka M; Oshima T; Hayashi S; Ishibashi C; Kobayashi S Eur J Pharmacol; 1973 Jun; 22(3):360-2. PubMed ID: 4732567 [No Abstract] [Full Text] [Related]